Update shared on20 Aug 2025
Fair value Increased 11%Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14.
Analyst Commentary
- Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.
- The acquisition represents a significant premium over prior valuations, leading to upward price target revisions.
- Analysts noted the strategic rationale of the acquisition for Alcon, viewing the price paid as attractive from the acquirer's perspective.
- Ratings were generally downgraded to Hold, reflecting limited further upside due to the acquisition terms now capping potential gains.
- The $1.5B enterprise value assigned in the deal was seen as setting the new benchmark valuation for STAA shares.
What's in the News
- Alcon Research, LLC agreed to acquire STAAR Surgical for $1.4 billion ($28 per share), with the transaction subject to regulatory and shareholder approvals and expected to close in six to 12 months.
- STAAR Surgical completed a share buyback, repurchasing 375,630 shares (0.76%) for $6.46 million.
- Deborah Andrews appointed Chief Financial Officer; she previously served as STAAR's CFO and held multiple finance leadership roles at the company.
- STAAR Surgical was added to multiple Russell value-oriented indices, including the Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, and Small Cap Comp Value, while being dropped from the Russell 2000 Defensive and Growth-Defensive indices.
Valuation Changes
Summary of Valuation Changes for STAAR Surgical
- The Consensus Analyst Price Target has risen from $22.11 to $24.14.
- The Consensus Revenue Growth forecasts for STAAR Surgical has significantly risen from 8.4% per annum to 18.2% per annum.
- The Net Profit Margin for STAAR Surgical has significantly risen from 3.34% to 4.07%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.